Humanistic Research Outcomes in Multiple Sclerosis: Review of the Literature from Latin America.

Epidemiology of Multiple Sclerosis in Latin America: Critical Analysis of the Literature.

Effect of Progressive Muscle Relaxation on the outcomes of Multiple Sclerosis disease: A systematic review and meta-analysis

Introduction: Multiple sclerosis (MS) is an inflammatory disease, makes damage in central nervous system. Evidence showed Progressive Muscle Relaxation (PMR) technique is one of the non-pharmacological methods used to treat MS. The purpose of the study was to determining the effect of PMR on the MS's outcomes in published papers in the field.  Method: This systematic and meta-analysis study we...

Update on riboflavin and multiple sclerosis: a systematic review

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS). Riboflavin plays an important role in myelin formation, and its deficiency is implicated as a risk factor for multiple sclerosis. Here, we systematically reviewed the literature concerning the health benefits of riboflavin on MS. The literature recorded within four main databases, including rel...

Cognitive and neuropsychiatric disorders among MS patients from Latin America

Cognitive and neuropsychiatric disorders in patients with multiple sclerosis have been extensively documented. The focus of this review will be on cognitive and neuropsychiatric disorders in multiple sclerosis patients from Latin America, in the context of international literature. Multicentre studies carried out in Latin America have shown that 43% of the patients have cognitive impairment and...

Use of Fingolimod in the Management of Relapsing–Remitting Multiple Sclerosis: Experience from Latin America

UNLABELLED Once-daily fingolimod 0.5 mg (FTY720; Gilenya(®), Novartis Pharma AG, Basel, Switzerland) is a sphingosine 1-phosphate receptor modulator that is approved for the treatment of relapsing multiple sclerosis (MS); currently, this includes approval in 13 Latin American countries. However, despite a well-characterized efficacy and safety profile in a large clinical development program, th...